Premium
Disparate clinical activity of PD‐1 blockade in melanoma subtypes: Know thy enemy!
Author(s) -
Bhatia Shailender,
Margolin Kim
Publication year - 2016
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30260
Subject(s) - blockade , melanoma , medicine , immune checkpoint , pd l1 , programmed cell death 1 , evasion (ethics) , cancer , metastatic melanoma , immunotherapy , immunology , immune system , cancer research , receptor
The 2 articles by Shousatri et al and Algazi et al in this issue of Cancer report the efficacy of programmed cell death receptor 1 (PD‐1) pathway blockade in metastatic acral/mucosal melanoma and uveal melanoma, respectively. The results point to the disparate activity of PD‐1 and PD‐1 ligand pathway blockade in these subtypes of melanoma and highlight the need to understand differences in the underlying biology of immune evasion in these and other malignancies as well as the need to identify mechanisms of success and failure of PD‐1 blockade. See also pages 3344‐53 and 3354‐62.